BRAF V600E in AML is rare (<1%, more in histiocytic disorders / mixed-phenotype acute leu...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRAF-V600E-AML |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-AML |
| Sources | SRC-CIVIC SRC-NCCN-AML-2025 |
Actionability Facts
| Biomarker | BIO-BRAF-V600E |
|---|---|
| Variant | V600E |
| Disease | DIS-AML |
| ESCAT tier | IIIB |
| Recommended combinations | dabrafenib + trametinib (off-label, case-report) |
| Evidence summary | BRAF V600E in AML is rare (<1%, more in histiocytic disorders / mixed-phenotype acute leukemia with histiocytic component). Tissue-agnostic dabrafenib + trametinib not approved in heme. Off-label use case-report level; consider in BRAF V600E AML with myeloid/dendritic mixed lineage. |
Notes
ESCAT IIIB. Distinct from histiocytic neoplasms (LCH, ECD) where BRAF V600E is the dominant driver — but those are not in our DIS list.
Used By
No reverse references found in the YAML corpus.